FDA now offers preliminary advice on whether a product in development could warrant a breakthrough designation, another seemingly lesser-known attempt at limiting the burden of reviewing formal requests to be part of the program.
Breakthrough In Two Pages: FDA Offers Preliminary Advice
Agency now allows sponsors of potential breakthrough therapies to request preliminary advice, but sponsors may not necessarily want to use it.